Inducible Forward Programming of Human Pluripotent Stem Cells to Hemato-endothelial Progenitor Cells with Hematopoietic Progenitor Potential.

Abstract

(Stem Cell Reports 14, 122–137; January 14, 2020) The authors wish to apologize for errors in the Supplemental Experimental Procedures. The units of the antibiotic concentrations were accidentally misrepresented as being in ng and g instead of μg. The units have now been corrected as follows: “Long term iPSC cultivation was performed as ML in CM in the presence of puromycin (0.3 μg mL−1) and/or zeocin (0.5 μg mL−1) (both InvivoGen, Toulouse, France) to prevent vector-silenced SLGE-iPSC throughout the cultivation.” “Puromycin (0.3 μg mL−1) and zeocin (0.5 μg mL−1) (both InvivoGen) were applied 24 h post-transduction.” These corrections do not influence the validity of the results or conclusions of this paper. Inducible Forward Programming of Human Pluripotent Stem Cells to Hemato-endothelial Progenitor Cells with Hematopoietic Progenitor PotentialLange et al.Stem Cell ReportsDecember 12, 2019In BriefLange, Schambach, and colleagues established an inducible hemato-endothelial forward programming protocol, utilizing the combinatorial and timely regulated overexpression of hematopoietic master regulators SCL, LMO2, GATA2, and ETV2 (SLGE). Regulated induction of this combination in SLGE-iPSCs generated large numbers of hemato-endothelial progenitor cells (CD144+/CD73–) capable of producing hematopoietic progenitor cells (CD45+/CD34+) with multi-lineage potential. Furthermore, transcriptome analysis identified potential regulators of definitive hematopoiesis. Full-Text PDF Open Access